Interaction of clindamycin and cefpimizole (U63196E) in vitro against aerobic gram-negative rods and aerobic gram-positive cocci.
The combination of clindamycin plus a new semisynthetic cephalosporin, U63196E for which the United States approved name is cefpimizole, was tested against 47 aerobic Gram-negative rods and 30 aerobic Gram-positive cocci. Synergy was seen with Klebsiella pneumoniae (3 of 19 isolates) and Escherichia coli (2 of 21 isolates). All isolates of Pseudomonas aeruginosa, Staphylococcus aureus, methicillin-resistant Staph. aureus, and enterococci demonstrated either indifference or antagonistic reactions to the drug combination.
D002511:Cephalosporins / Q000494:pharmacology*; D002981:Clindamycin / Q000494:pharmacology*; D004347:Drug Interactions; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D008826:Microbial Sensitivity Tests
D002511:Cephalosporins; C038845:cefpimizole; D002981:Clindamycin